BRPI0112986B8 - compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos - Google Patents

compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos

Info

Publication number
BRPI0112986B8
BRPI0112986B8 BRPI0112986A BR0112986A BRPI0112986B8 BR PI0112986 B8 BRPI0112986 B8 BR PI0112986B8 BR PI0112986 A BRPI0112986 A BR PI0112986A BR 0112986 A BR0112986 A BR 0112986A BR PI0112986 B8 BRPI0112986 B8 BR PI0112986B8
Authority
BR
Brazil
Prior art keywords
compounds
preparation
well
pharmaceutical compositions
azabicyclic
Prior art date
Application number
BRPI0112986A
Other languages
English (en)
Other versions
BR0112986B1 (pt
BR0112986A (pt
Inventor
Fromentin Claude
Alan Rowlands David
Aszodi Jozsef
Lampilas Maxime
Original Assignee
Astra Zeneca Holding France
Aventis Pharma Sa
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8853181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0112986(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France, Aventis Pharma Sa, Novexel filed Critical Astra Zeneca Holding France
Publication of BR0112986A publication Critical patent/BR0112986A/pt
Publication of BR0112986B1 publication Critical patent/BR0112986B1/pt
Publication of BRPI0112986B8 publication Critical patent/BRPI0112986B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"compostos azabicíclicos, o respectivo preparo e a respectiva utilização como medicamentos, notadamente como antibacteriano". a invenção se refere aos novos compostos heterocíclicos de fórmula geral (i), e seus sais com uma base ou um ácido. a invenção se refere igualmente a um processo para o preparo desses compostos, assim como sua utilização como medicamentos, notadamente como agentes anti-bacterianos.
BRPI0112986A 2000-08-01 2001-07-24 compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos BRPI0112986B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0010121 2000-08-01
FR0010121A FR2812635B1 (fr) 2000-08-01 2000-08-01 Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
PCT/FR2001/002418 WO2002010172A1 (fr) 2000-08-01 2001-07-24 Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens

Publications (3)

Publication Number Publication Date
BR0112986A BR0112986A (pt) 2003-07-08
BR0112986B1 BR0112986B1 (pt) 2014-04-01
BRPI0112986B8 true BRPI0112986B8 (pt) 2021-05-25

Family

ID=8853181

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112986A BRPI0112986B8 (pt) 2000-08-01 2001-07-24 compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos

Country Status (41)

Country Link
US (5) US7112592B2 (pt)
EP (1) EP1307457B1 (pt)
JP (2) JP4515704B2 (pt)
KR (1) KR100632906B1 (pt)
CN (1) CN1289500C (pt)
AP (1) AP1614A (pt)
AR (1) AR031716A1 (pt)
AT (1) ATE263768T1 (pt)
AU (2) AU2001279905B2 (pt)
BG (1) BG66094B1 (pt)
BR (1) BRPI0112986B8 (pt)
CA (1) CA2417475C (pt)
CR (1) CR6895A (pt)
CZ (1) CZ294956B6 (pt)
DE (1) DE60102702T2 (pt)
DK (1) DK1307457T3 (pt)
DZ (1) DZ3397A1 (pt)
EA (1) EA004920B1 (pt)
EC (1) ECSP034460A (pt)
EE (1) EE05183B1 (pt)
ES (1) ES2220793T3 (pt)
FR (1) FR2812635B1 (pt)
HR (1) HRP20030034B1 (pt)
HU (1) HU226889B1 (pt)
IL (2) IL154187A0 (pt)
MA (1) MA26938A1 (pt)
ME (2) MEP17108A (pt)
MX (1) MXPA03000881A (pt)
NO (1) NO324940B1 (pt)
NZ (1) NZ523707A (pt)
OA (1) OA12347A (pt)
PL (2) PL234468B1 (pt)
PT (1) PT1307457E (pt)
RS (1) RS50214B (pt)
SI (1) SI1307457T1 (pt)
SK (1) SK287597B6 (pt)
TR (1) TR200400859T4 (pt)
TW (1) TWI292401B (pt)
UA (1) UA73791C2 (pt)
WO (1) WO2002010172A1 (pt)
ZA (1) ZA200300676B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) * 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
WO2007065288A2 (en) 2005-12-07 2007-06-14 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
PT2041156E (pt) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
EP2069347A2 (en) * 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
KR20090064463A (ko) * 2006-10-23 2009-06-18 아이알엠 엘엘씨 카텝신 프로테아제 억제제
JPWO2008093737A1 (ja) 2007-01-31 2010-05-20 大日本住友製薬株式会社 アミド誘導体
FR2914923B1 (fr) * 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
WO2009091856A2 (en) * 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US8518934B2 (en) 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
US20120053350A1 (en) * 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
KR20120109292A (ko) 2009-06-24 2012-10-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Ｎ-치환-시클릭 아미노 유도체
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
PL2657234T3 (pl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Optycznie czynna pochodna diazabicyklooktanowa i sposób jej wytwarzania
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
RU2610091C2 (ru) * 2011-06-17 2017-02-07 Астразенека Аб (2S,5R)-5-[(бензилокси)амино]пиперидин-2-карбоксамид
MX348974B (es) * 2011-08-27 2017-07-04 Wockhardt Ltd Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CA2845108C (en) * 2011-08-30 2015-06-16 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
CA2846107C (en) * 2011-09-13 2016-06-21 Wockhardt Limited Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
RU2614418C2 (ru) * 2012-08-25 2017-03-28 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение для лечения бактериальных инфекций
SG11201503427TA (en) 2012-11-01 2015-06-29 Kaneka Corp Process for producing optically active bicyclic urea compound
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
IN2015DN02381A (pt) 2013-02-19 2015-09-04 Api Corp
US9567335B2 (en) * 2013-03-08 2017-02-14 Wockhardt Limited Process for sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
BR112015021332B1 (pt) * 2013-03-08 2020-06-30 Wockhardt Limited sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
WO2014200786A1 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Preparation of tert-butyl 4-((1r,2s,5r)-6- (benzyloxy)-7-0x0-1,6-diazabicycl0[3.2.i]octane-2- carboxamido)piperidine-1-carboxylate
JP6453222B2 (ja) 2013-09-24 2019-01-16 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
ES2901198T3 (es) 2013-10-08 2022-03-21 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas
IN2013MU03216A (pt) 2013-10-11 2015-07-03 Wockhardt Ltd
WO2015112441A1 (en) 2014-01-22 2015-07-30 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
EP3139918B1 (en) 2014-05-09 2019-12-25 Merck Sharp & Dohme Corp. Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
JP6764862B2 (ja) * 2014-11-17 2020-10-07 エンタシス・セラピューティックス・リミテッド 耐性細菌感染症の治療のための併用療法
ES2812848T3 (es) 2014-12-02 2021-03-18 Merck Sharp & Dohme Proceso para la preparación de 4-((2S,5R)-6-(benciloxi)-7-oxo-1,6-diazabiciclo[3.2.1]octano-2-carboxamido)piperidin-1-carboxilato de terc-butilo y análogos del mismo
MY190283A (en) 2014-12-05 2022-04-12 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10667737B2 (en) 2015-03-23 2020-06-02 International Business Machines Corporation Monitoring a person for indications of a brain injury
KR102713561B1 (ko) * 2015-05-07 2024-10-08 무타빌리스 헤테로사이클릭 화합물 및 세균성 감염을 예방 또는 치료하는 이의 용도
EP3091018A1 (en) * 2015-05-07 2016-11-09 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2016206101A1 (en) 2015-06-26 2016-12-29 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
US10265326B2 (en) 2015-08-10 2019-04-23 Sandoz Ag Form C of avibactam sodium
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
EP3281942A4 (en) 2015-09-16 2018-08-15 Xuanzhu Pharma Co., Ltd. B-lactamase inhibitor and application thereof
CN107532185B (zh) 2015-10-02 2023-01-06 株式会社Api 羟基-l-哌可酸的制造方法
KR20180051559A (ko) 2015-10-02 2018-05-16 주식회사 레고켐 바이오사이언스 베타-락타마제의 억제용 조성물 및 억제 방법
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
WO2017136254A1 (en) 2016-02-04 2017-08-10 Merck Sharp & Dohme Corp. Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents
CN105753867B (zh) * 2016-03-24 2018-03-27 齐鲁制药有限公司 一种改进的阿维巴坦钠中间体化合物的制备方法
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
EP3504207B1 (en) * 2016-08-26 2022-06-01 Sandoz AG Avibactam free acid
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN110392684A (zh) * 2017-02-06 2019-10-29 拜欧蒂姆公司 新型杂环化合物及其在预防或治疗细菌感染中的用途
WO2018208769A1 (en) 2017-05-08 2018-11-15 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
WO2019018186A1 (en) 2017-07-17 2019-01-24 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors and methods of use thereof
EP3676247B8 (en) 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
JP7289836B2 (ja) 2017-11-23 2023-06-12 エフ． ホフマン－ラ ロシュ アーゲー プロリンヒドロキシラーゼ、ならびにそれに伴う使用、方法および生成物
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CA3114618C (en) 2018-10-01 2023-09-05 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
CN111072660B (zh) * 2018-10-22 2021-05-18 新发药业有限公司 一种瑞来巴坦的简便制备方法
JP2022524118A (ja) 2019-03-12 2022-04-27 アリクサ ファーマシューティカルズ、インコーポレイテッド アビバクタム誘導体の結晶形
US11565999B2 (en) 2019-04-25 2023-01-31 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
CN110078728B (zh) * 2019-05-23 2020-10-23 江西富祥药业股份有限公司 一种阿维巴坦中间体、制备方法及其应用
WO2021106864A1 (en) * 2019-11-25 2021-06-03 Eisai R&D Management Co., Ltd. Process for the preparation of producing pyrazolo[1,5-a] pyrimidine derivatives
CN115151544B (zh) 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
CN115605480B (zh) 2021-05-07 2024-04-05 宁夏农林科学院 磺酰脒取代的化合物及其作为β-内酰胺酶抑制剂的用途
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
AU2024317688A1 (en) 2023-08-01 2026-03-12 Fresenius Kabi Oncology Ltd. An improved process for the preparation of avibactam and intermediate thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4939678B1 (pt) * 1968-05-06 1974-10-28
US4024147A (en) * 1972-06-30 1977-05-17 John Wyeth & Brother Limited Heterocyclic compounds
US4049821A (en) * 1976-05-12 1977-09-20 A. H. Robins Company, Inc. Method of treating allergy
EP0260057A3 (en) * 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
JPS63119471A (ja) * 1986-09-02 1988-05-24 ザ・ユニバーシテイ・オブ・メルボルン ２−オキソ−４−カルボキシ−ピリミジン
CZ282567B6 (cs) * 1993-12-29 1997-08-13 Pfizer Inc. Diazabicyklické sloučeniny a farmaceutické prostředky na jejich bázi
TW358097B (en) * 1996-05-24 1999-05-11 Hoffmann La Roche Beta-lactams and their process and pharmaceutical compositions
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
JP3505189B2 (ja) * 1997-02-10 2004-03-08 ファイザー・プロダクツ・インク ２−アミノ−６−（２−置換−４−フェノキシ）−置換ピリジン
US6060585A (en) * 1997-03-04 2000-05-09 Wisconsin Alumni Research Foundation β-polypeptide foldamers of well-defined secondary structure
KR100207096B1 (ko) * 1997-07-08 1999-07-15 이명환 시사프라이드의 제조 방법
US6384080B1 (en) * 1998-04-20 2002-05-07 Fujisawa Pharmaceutical Co., Ltd. Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase
GB9817029D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
FR2784682B1 (fr) * 1998-10-15 2002-12-06 Hoechst Marion Roussel Inc Nouveaux derives 2-halogene de 5-0-desosaminylerythronolide a, leur procede de preparation et leur application comme medicaments
ATE272633T1 (de) * 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
KR20010101355A (ko) * 1999-01-02 2001-11-14 로버트 흐라이탁, 미쉘 베스트 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 ｘａ 활성 억제)
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Also Published As

Publication number Publication date
MEP17108A (en) 2010-06-10
AP1614A (en) 2006-05-21
ME00060B (me) 2010-06-10
CA2417475C (en) 2010-04-20
US7112592B2 (en) 2006-09-26
HU226889B1 (en) 2010-01-28
BG107497A (bg) 2003-09-30
DE60102702T2 (de) 2005-04-07
CR6895A (es) 2007-07-12
BR0112986B1 (pt) 2014-04-01
OA12347A (fr) 2006-05-15
US20110213147A1 (en) 2011-09-01
JP4515704B2 (ja) 2010-08-04
HUP0302943A2 (hu) 2003-12-29
EA004920B1 (ru) 2004-10-28
NO20030494D0 (no) 2003-01-31
RS50214B (sr) 2009-07-15
BR0112986A (pt) 2003-07-08
FR2812635A1 (fr) 2002-02-08
JP2004505088A (ja) 2004-02-19
DZ3397A1 (fr) 2002-02-07
IL154187A (en) 2009-02-11
CN1468242A (zh) 2004-01-14
US8178554B2 (en) 2012-05-15
PL365162A1 (en) 2004-12-27
PT1307457E (pt) 2004-08-31
NO324940B1 (no) 2008-01-07
US20060189652A1 (en) 2006-08-24
MXPA03000881A (es) 2003-06-06
PL401469A1 (pl) 2013-02-04
US7638529B2 (en) 2009-12-29
JP2010138206A (ja) 2010-06-24
DK1307457T3 (da) 2004-08-09
AU7990501A (en) 2002-02-13
SI1307457T1 (en) 2004-08-31
ATE263768T1 (de) 2004-04-15
US20110021772A1 (en) 2011-01-27
SK287597B6 (sk) 2011-03-04
HRP20030034B1 (hr) 2011-03-31
KR100632906B1 (ko) 2006-10-13
EP1307457B1 (fr) 2004-04-07
IL154187A0 (en) 2003-07-31
ECSP034460A (es) 2003-03-10
US7732610B2 (en) 2010-06-08
NZ523707A (en) 2005-02-25
CN1289500C (zh) 2006-12-13
EP1307457A1 (fr) 2003-05-07
NO20030494L (no) 2003-03-28
EA200300211A1 (ru) 2003-06-26
HRP20030034A2 (en) 2004-02-29
TWI292401B (en) 2008-01-11
SK1052003A3 (en) 2003-11-04
UA73791C2 (uk) 2005-09-15
AR031716A1 (es) 2003-10-01
YU6303A (sh) 2006-03-03
FR2812635B1 (fr) 2002-10-11
CZ2003223A3 (cs) 2003-08-13
HK1060356A1 (en) 2004-08-06
CZ294956B6 (cs) 2005-04-13
US20060046995A1 (en) 2006-03-02
AP2003002726A0 (en) 2003-06-30
KR20030019642A (ko) 2003-03-06
EE200300046A (et) 2004-10-15
EE05183B1 (et) 2009-06-15
PL216028B1 (pl) 2014-02-28
HUP0302943A3 (en) 2007-08-28
CA2417475A1 (fr) 2002-02-07
PL234468B1 (pl) 2020-02-28
BG66094B1 (bg) 2011-04-29
AU2001279905B2 (en) 2005-12-08
DE60102702D1 (de) 2004-05-13
ZA200300676B (en) 2004-05-10
US20030199541A1 (en) 2003-10-23
TR200400859T4 (tr) 2004-06-21
ES2220793T3 (es) 2004-12-16
MA26938A1 (fr) 2004-12-20
WO2002010172A1 (fr) 2002-02-07

Similar Documents

Publication Publication Date Title
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BRPI0509368A (pt) antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BR0315642A (pt) Antagonistas de cgrp selecionados, processo para sua preparação, bem como seu uso como medicamento
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0009641A (pt) Derivados de 1,4-benzotiazepin-1,1-dióxido, substituìdos com radicais de açúcar, processo para produção dos mesmos, medicamentos contendo esses compostos e sua utilização
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BRPI0412291A (pt) antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
BRPI0407387A (pt) Derivados de hexahidro-pirazino[1,2-a]pirimidin-4,7-diona substituìdos por nitrogênio, processos para a sua preparação e sua aplicação com medicamento
BRPI0411713B8 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
BRPI0109200B8 (pt) compostos e composições farmacêuticas
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0212158A (pt) Derivados de diarilcicloalquila, processos para a sua preparação e sua aplicação como ativadores de ppar
BR9912188A (pt) Derivados de 1,1-dióxido de benzo (b) tiepina, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0116571A (pt) Compostos heterocìclicos tendo atividade antibacteriana, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR0311896A (pt) Difenilazetidinonas substituìdas com grupos ácidos, processo para sua preparação, medicamentos contendo estes compostos e seu uso
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BR0017063A (pt) Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las
BR0308765A (pt) Compostos (4,2-dissubstituìdo-tiazol-5-il)amina como inibidores de pde7

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVEXEL (FR)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA SA

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/04/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/07/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/07/2021